Our recent study identified that METTL3 inhibition reduced cellular proliferation in PCa cells [68] and thus the investigation of such METTL3-targeted therapies to benefit PCa patients is warranted (Fig. 4). This evidence concerns the gene METTL3 and posterior cortical atrophy.